RVP RETRACTABLE TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 946563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY5.3%
TTM EPS YoY4.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin-5.2%
Operating margin-61.1%
Net margin-16.1%
FCF margin—
EBITDA margin-40.4%
Returns
ROE-8.3%
ROA-4.3%
ROIC (approx.)-25.6%
Asset turnover0.27x
Leverage & solvency
Liabilities / assets49.2%
Debt / equity0.00x
Current ratio4.54x
Interest coverage-299.43x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.13M | $7.20M | $7.18M | $9.44M | $10.09M | $10.45M | $8.30M | $9.07M |
| Cost of revenue | $13.93M | $7.01M | $8.02M | $10.97M | $8.40M | $10.55M | $8.30M | $11.57M |
| Gross profit | $193,247 | $190,852 | -$838,408 | -$1.53M | $1.69M | -$107,090 | -$1,911 | -$2.49M |
| R&D expense | $147,535 | $187,291 | $170,416 | $124,864 | $199,462 | $160,049 | $191,192 | $157,894 |
| SG&A expense | $2.99M | $3.61M | $3.43M | $3.13M | $3.56M | $3.20M | $2.88M | $3.38M |
| Operating income | -$4.14M | -$5.15M | -$6.17M | -$7.71M | -$3.65M | -$5.13M | -$4.68M | -$7.22M |
| Interest expense | $16,618 | $18,705 | $20,441 | $21,609 | $20,585 | $22,257 | $23,455 | $26,711 |
| Pretax income | -$2.36M | $2.83M | -$4.22M | -$2.35M | $372,740 | -$85,657 | -$10.21M | $3.77M |
| Income tax | $1,346 | $1,837 | $1,837 | $2,024 | $1,693 | $1,814 | $285,761 | $1,990 |
| Net income | -$2.36M | $2.83M | -$4.23M | -$2.35M | $371,047 | -$87,471 | -$10.50M | $3.77M |
| EBITDA | -$2.24M | -$3.25M | -$4.26M | -$5.57M | -$1.79M | -$3.26M | -$2.79M | -$5.33M |
| EPS (basic) | -0.08 | 0.09 | -0.14 | — | 0.01 | 0.00 | -0.35 | — |
| EPS (diluted) | -0.08 | 0.09 | -0.14 | — | 0.01 | 0.00 | -0.35 | — |
| Weighted avg. shares (diluted) | 29.94M | 29.94M | 29.94M | — | 29.94M | 29.94M | 29.94M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.89M | $2.64M | $2.77M | $2.59M | $3.44M | $3.04M | $3.38M | $4.24M |
| Receivables | $14.31M | $9.03M | $6.98M | $7.90M | $8.44M | $8.09M | $5.36M | $7.79M |
| Inventory | $10.12M | $15.93M | $16.43M | $17.19M | $20.39M | $20.45M | $21.18M | $19.19M |
| Current assets | $64.64M | $65.92M | $59.96M | $63.08M | $64.13M | $63.00M | $63.66M | $73.27M |
| PP&E, net | $73.65M | $75.47M | $77.31M | $79.18M | $82.24M | $84.01M | $85.55M | $87.35M |
| Total assets | $138.55M | $141.69M | $137.60M | $142.63M | $146.43M | $147.09M | $149.31M | $160.72M |
| Current liabilities | $14.23M | $13.37M | $10.45M | $9.60M | $9.63M | $8.99M | $9.50M | $8.78M |
| Short-term debt | — | — | — | — | $359,102 | $349,962 | $343,216 | $332,480 |
| Long-term debt | — | — | — | $895,645 | $623,605 | $717,530 | $807,390 | $900,042 |
| Total debt | — | — | — | $895,645 | $982,707 | $1.07M | $1.15M | $1.23M |
| Total liabilities | $68.10M | $68.83M | $67.50M | $68.26M | $69.65M | $70.62M | $72.70M | $73.55M |
| Shareholders' equity | $70.45M | $72.87M | $70.09M | $74.38M | $76.78M | $76.47M | $76.61M | $87.17M |
| Net debt | — | — | — | -$1.69M | -$2.46M | -$1.98M | -$2.23M | -$3.00M |
| Shares outstanding | 29.94M | 29.94M | 29.94M | 29.94M | 29.94M | 29.94M | 29.94M | 29.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$248,232 | -$1.73M | -$1.37M | -$596,542 | -$1.26M | -$3.73M | -$1.48M | -$1.10M |
| Capital expenditure | $53,566 | $29,823 | $6,227 | — | $89,788 | $332,250 | $87,034 | $298,058 |
| Free cash flow | -$301,798 | -$1.76M | -$1.37M | — | -$1.35M | -$4.07M | -$1.56M | -$1.40M |
| Investing cash flow | -$326,455 | $1.81M | $1.69M | -$114,698 | $1.80M | $3.54M | $762,239 | $1.56M |
| Financing cash flow | -$175,440 | -$198,146 | -$146,823 | -$144,673 | -$142,396 | -$140,725 | -$139,527 | -$136,996 |
| Depreciation & amortization | $1.90M | $1.90M | $1.90M | $2.14M | $1.87M | $1.87M | $1.88M | $1.89M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.